WASHINGTON (AP) — Federal regulators say approval of the first generic version of cancer drug Doxil will help resolve a lingering shortage triggered by manufacturing deficiencies.
The shortage of the Johnson & Johnson injectable medication, made under contract by Ben Venue Laboratories, has continued on and off for a few years. It's resulted in rationing, with some patients with ovarian and other cancers getting less-effective care, and disrupted studies testing Doxil against possible new treatments.
The Food and Drug Administration says it's approved a generic version, called doxorubicin, made by Sun Pharma Global FZE. Last February, the FDA authorized temporary importation from India of a brand-name version, called Lipodox, also made by Sun Pharma. It's a subsidiary of an Indian drugmaker.
Meanwhile, J&J continues to seek a contract manufacturer to replace Ben Venue.
The truth about gun deaths: numbers and actual solutions
Cortney O'Brien - "Do You Get How Bad it Looks?": Today Show Grills Hillary on Emails
You will be DISGUSTED by what racist Salon called Michelle Malkin
She's Afraid of Her Tenant
Congressional Reform Goes Beyond Electing the Right Speaker | RedState
The War on America Turns 50 | Human Events
Unhinged Daily News Writer Wants NRA Designated A "Terrorist Group" - Bearing Arms - libel, Linda Stasi, media bias, New York Daily News, NRA